Equities Analysts Offer Predictions for MIRM Q2 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.36) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $2.09 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same quarter in the previous year, the business posted ($0.54) earnings per share. The company’s revenue was up 61.2% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on the stock. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. JMP Securities boosted their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a report on Friday, May 9th. Finally, Raymond James restated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $60.73.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $45.34 on Wednesday. The company has a market capitalization of $2.25 billion, a PE ratio of -22.45 and a beta of 0.95. Mirum Pharmaceuticals has a twelve month low of $23.83 and a twelve month high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The business’s 50-day moving average price is $42.97 and its 200 day moving average price is $44.55.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. MPM Bioimpact LLC lifted its stake in shares of Mirum Pharmaceuticals by 19.7% during the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company’s stock valued at $24,379,000 after acquiring an additional 96,856 shares during the period. AlphaQuest LLC grew its stake in shares of Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock worth $76,000 after purchasing an additional 1,658 shares during the period. Golden State Equity Partners increased its holdings in Mirum Pharmaceuticals by 1,390.8% in the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock valued at $801,000 after purchasing an additional 18,080 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Mirum Pharmaceuticals in the fourth quarter valued at about $277,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $413,000.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, Director Patrick J. Heron purchased 1,335 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of $45.57 per share, with a total value of $60,835.95. Following the acquisition, the director now directly owns 163,643 shares of the company’s stock, valued at approximately $7,457,211.51. This trade represents a 0.82% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the transaction, the senior vice president now directly owns 4,841 shares of the company’s stock, valued at $214,698.35. This represents a 92.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 92,764 shares of company stock worth $4,109,161 over the last three months. 14.36% of the stock is currently owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.